Search
                    Tirzepatide Treatment Options in Buffalo, NY
A collection of 5 research studies where Tirzepatide is the interventional treatment. These studies are located in the Buffalo, NY. Tirzepatide is used for conditions such as Obesity, Overweight and Type 2 Diabetes.
            1 - 5 of 5
        
        
    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Lose Weight with Tirzepatide
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss.
    Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    Featured Trial
                
                Paid Clinical Studies Nationwide
            
        Recruiting
            
        Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
    
    
Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    
                
                                    A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
                                
            
            
        Completed
                            
            
                The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.             
        
        
    Gender:
                ALL
            Ages:
                40 years and above
            Trial Updated:
                08/15/2025
            
            Locations: Erie County Medical Center, Buffalo, New York  +3 locations         
        
        
            Conditions: Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
        
            
        
    
                
                                    A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
                                
            
            
        Recruiting
                            
            
                The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits.
Participants who have completed the primary 72-week GPIX study and have been off treatment for no more than 12 weeks (including the 4-week safety follow-up period), will have the o...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 12 years and 17 years
            Trial Updated:
                08/15/2025
            
            Locations: UBMD Pediatrics, Buffalo, New York  +1 locations         
        
        
            Conditions: Obesity, Weight Gain
        
            
        
    
                
                                    A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
                                
            
            
        Recruiting
                            
            
                The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/17/2025
            
            Locations: Albany Medical College, Division of Community Endocrinology, Albany, New York  +3 locations         
        
        
            Conditions: Type 1 Diabetes, Obesity, Overweight
        
            
        
    
                
                                    A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
                                
            
            
        Active Not Recruiting
                            
            
                This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/17/2025
            
            Locations: Research Foundation of SUNY - University of Buffalo, Buffalo, New York         
        
        
            Conditions: Type 2 Diabetes
        
            
        
    
                
                                    A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
                                
            
            
        Completed
                            
            
                The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 80 years
            Trial Updated:
                01/22/2025
            
            Locations: Montefiore Medical Center, Bronx, New York  +3 locations         
        
        
            Conditions: Nonalcoholic Steatohepatitis
        
            
        
    1 - 5 of 5
            
            
        